Additionally, our previous research proved that CD4+CD25hiCD127low Tregs in peripheral blood had great value for the selection of appropriate individualized treatment options for patients with non-small cell lung cancer [19]. This evidence concerns the gene CD4 and non-small cell lung carcinoma.